HemOnc vocabulary relationships

From HemOnc.org - A Hematology Oncology Wiki
(Redirected from Vocabulary relationships)
Jump to: navigation, search

The purpose of this page is to describe the existing relationships in the HemOnc ontology and to give examples. Most of the examples are based on adjuvant CapeOx for colon cancer, as described in the XELOXA study's primary publication (Schmoll et al. 2007, JCO). You can also follow this link to the Concepts page.

Common internal relationships and examples

These relationships occur at least 100 times in the most recent version of the ontology.

Concept Type 1 Relationship Concept Type 2 Example 1 Relationship Example 2
Regimen Can be followed by Regimen 7 plus 3i (induction) Can be followed by HiDAC (consolidation)
Regimen Can be followed by Procedure FEC (neoadjuvant) Can be followed by Surgery
Regimen Can be preceded by Regimen HiDAC (consolidation) Can be preceded by 7 plus 3i (induction)
Regimen Can be preceded by Procedure CapeOx (adjuvant) Can be preceded by Surgery
Component Has accepted use Condition Capecitabine Has accepted use Colon cancer
Regimen Has accepted use Condition CapeOx Has accepted use Colon cancer
Regimen Has antineoplastic Component CapeOx Has antineoplastic Capecitabine
Regimen Has immunosuppressor Component Dexamethasone monotherapy Has immunosuppressor Dexamethasone
Regimen Has local therapy Component IT Cytarabine & Methotrexate Has local therapy Cytarabine
Regimen Has supportive med Component Carboplatin & Pemetrexed Has supportive med Dexamethasone
Regimen Has supportive med Component Class Bortezomib monotherapy Has supportive med Bisphosphonate
Regimen Has been compared to Regimen CapeOx Has been compared to FULV
Regimen Has been compared to Regimen Stub CapeOx Has been compared to FUFOX
Component Has brand name Brand Name Capecitabine Has brand name Xeloda
Regimen Has context Context CapeOx Has context Adjuvant therapy
Component Has FDA indication Condition Capecitabine Has FDA indication Colon cancer
Reference Has first author Author XELOXA::00 Has first author Schmoll_Hans Joachim
Reference Has middle author Author XELOXA::00 Has middle author Tabernero_Jose M
Reference Has last author Author XELOXA::00 Has last author Haller_Daniel G
Regimen Has modality Modality CapeOx Has modality Chemotherapy
Reference Has PMID PubMedURL XELOXA::00 Has PMID https://pubmed.ncbi.nlm.nih.gov/17194911
Reference Has URL ReferenceURL XELOXA::00 Has URL https://doi.org/10.1200/jco.2006.08.1075
Reference Has title ReferenceTitle XELOXA::00 Has title Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patients
Regimen Is current in Condition CapeOx Is current in Colon cancer
Regimen Is historical in Condition Edrecolomab monotherapy Is historical in Colon cancer
Component Was FDA approved Year Capecitabine Was FDA approved 1998
Reference Was published in Journal XELOXA::00 Was published in J Clin Oncol
Reference Was published year Year XELOXA::00 Was published year 2007
Regimen Has cycle Cycle Sigs CapeOx Has cycle 21-day cycle for 8 cycles
Study Has reference Reference XELOXA Has reference XELOXA::00
Study Has reported endpt Endpoint XELOXA Has reported endpt OS
Study Had experimental design Experimental design XELOXA Had experimental design In-class switch
Component Has route Route Capecitabine Has route PO
Study Has study group Study Group ECOG E3200 Has study group Eastern Cooperative Oncology Group
Study Has study short name Study name short XELOXA Has study short name Schmoll et al. 2007
Study Has study type Study Class X-ACT Has study type FDA registration study
Component Has sig Sig Capecitabine Has sig 1000 mg/m^2 PO twice per day on days 1 to 14
Component Has sig Sig Stub Capecitabine Has sig 1660 mg/m^2/day PO on days 1 to 21 (frequency of dosing not specified)
Component Class Has sig Sig Stub Serotonin 5-HT3 antagonist Has sig on the day of IV chemotherapy
Component Is a Component Class Capecitabine Is a Fluoropyrimidine
Component Class Is a Component Class Fluoropyrimidine Is a Pyrimidine analogue
Condition Is a Condition Colon cancer Is a Colorectal cancer
Regimen Is a Regimen Class CapeOx Is a Platinum doublet
Component May have route Route Dexamethasone May have route PO
Regimen Was studied in Study CapeOx Was studied in XELOXA
Context Was studied in Study Adjuvant therapy Was studied in XELOXA
Condition Was studied in Study Colon cancer Was studied in XELOXA

Uncommon internal relationships and examples

These relationships occur less than 100 times in the most recent version of the ontology. This list is currently incomplete.

Concept Type 1 Relationship Concept Type 2 Example 1 Relationship Example 2
Context Is a Context Adjuvant therapy Is a Post-definitive therapy
Regimen Has immunosuppressor Component Class Fludarabine & Melphalan Has immunosuppressor ATG (type not specified)
Regimen Has been compared to Procedure Cisplatin, Fluorouracil, RT Has been compared to Surgery
Regimen Has been compared to Regimen Class Ipilimuamb & Nivolumab Has been compared to Platinum doublet

Common external relationships and examples

These relationships occur at least 100 times in the most recent version of the ontology.

Concept Type 1 Relationship Concept Type 2 Example 1 Relationship Example 2
Regimen Has antineopl Rx RxNorm CUI CapeOx Has antineopl Rx 194000
Regimen Has immunosuppr Rx RxNorm CUI Dexamethasone monotherapy Has immunosuppr Rx 3264
Regimen Has local therap Rx RxNorm CUI CHOP-14 Has local therap Rx 3041
Regimen Has support med Rx RxNorm CUI Carboplatin & Pemetrexed Has support med Rx 3264
Component Maps to RxNorm CUI Capecitabine Maps to 194000
Condition Maps to NCIT CUI Colon cancer Maps to C4910

Uncommon external relationships and examples

These relationships occur less than 100 times in the most recent version of the ontology.

Concept Type 1 Relationship Concept Type 2 Example 1 Relationship Example 2
Regimen Has antineopl Rx RxNorm Extension CUI Pixantrone monotherapy Has antineopl Rx OMOP997118
Component Maps to RxNorm Extension CUI Pixantrone Maps to OMOP997118

Further explanation of some relationships

Can be followed by

This directed relationship is phrased as an optional because there is always the possibility, even in a pre-defined protocol, that the patient will not go on to receive the second (or third, etc.) part of a treatment protocol.

Can be preceded by

This directed relationship is phrased as an optional because it is contextual; in many treatment contexts it is not necessary that the first treatment occurs before the second. In some treatment contexts the relationship is absolute, e.g., chemotherapy given in the adjuvant setting must by definition be preceded by a surgical procedure. This subtle distinction is not yet captured by the ontology.

Has been compared to

This non-directional relationship is the pairwise comparison of two regimens in a randomized clinical trial. In the most common scenario one regimen is a control arm and the other is experimental arm, although this is not always the case.

Has FDA indication

With very few exceptions, the FDA approves drugs, not regimens. Currently, all of these relationships in HemOnc are between components (drugs) and conditions.

Has reported endpt

For "negative" studies, which we define as those having p>0.10 regardless of the predeclared level of alpha, the reported endpoint is the primary endpoint. For "positive" studies, the reported endpoint is that which is the least surrogate with a p<0.10.

Has route and May have route

Components with only one route of administration are related to that route using "Has route". Conversely, components with multiple routes of administration are related to those routes using "May have route".

Has study type

Right now there is only one defined study class: FDA registration trials. We will plan to expand this in the near future to include details such as phase of study, whether a study was a cooperative group trial, etc.

Was replaced by

This is a special relationship type used to associate current and deprecated concepts. For example, "Imatinib monotherapy, high dose" has been replaced by "Imatinib monotherapy" and the replacement is captured by this relationship.